TwitterFacebookInstagramPinterestYouTubeTumblrRedditWhatsAppThreads

NHRC Issues Notices Over Failed Quality Test of Epilepsy Drug ‘Sodium Valproate’

NHRC Issues Notices Over Failed Quality Test of Epilepsy Drug ‘Sodium Valproate’

NHRC Issues Notices Over Failed Quality Test of Epilepsy Drug ‘Sodium Valproate’

The National Human Rights Commission (NHRC) in India took suo motu cognizance of a media report indicating that ‘Sodium Valproate,’ a medication prescribed for epilepsy treatment in Delhi government-run hospitals and Mohalla Clinics, did not meet the required standards in a quality test conducted by the Regional Drug Testing Laboratory (RDTL) in Chandigarh. This issue was raised in a press release by the NHRC.

As per the media report cited, the Directorate of Vigilance released findings indicating that, out of a total of 43 medicine samples examined by government laboratories, four samples failed the quality test. Additionally, the report for 11 samples is yet to be disclosed. The release highlighted that another medicine recommended for epilepsy treatment also showed inadequacy.

Expressing concern over potential human rights violations if the reported findings are accurate, the NHRC issued notices to key authorities, including the Delhi Chief Secretary, the Drugs Controller General of India, and the Police Commissioner, seeking a comprehensive report within four weeks.

The press release also mentioned that as of December 28, five medicines, including those prescribed for conditions such as hypertension, excess acid influx, joint pain, and lung swelling, have been banned due to similar concerns raised by the media report.

The NHRC’s proactive step aims to address potential violations and ensure the safety and efficacy of medications administered to patients, specifically targeting the quality of drugs distributed for critical health conditions like epilepsy.

VoM News Desk
VoM News Desk

VoM News is an online web portal in jammu Kashmir offers regional, National & global news.

Scroll to Top